Frontlight ResearchEarly access
CompletedPhase 3
A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2)
Key facts
- Who runs it
- Keymed Biosciences Co.Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 180 people enrolled
- Started
- 9 Aug 2022
- Ended
- 25 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CM310
- Placebo
- Record updated
- 8 November 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- with chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity
- NCS score of 2 or 3 at screening period, and at least 2 at baseline
- Contraception
Who cannot take part
- Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy)
- Vaccination with live attenuated vaccine within 12 weeks before randomization or during the planned study period
- With malignant or benign tumor of nasal cavity
- Participated and any studies of CM310
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM310, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM310 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
The 2 groups in the trial
- CM310Treatment being tested
CM310 300mg is given subcutaneously (SC) every two weeks
Treatment: Placebo
- PlaceboPlacebo, for comparison
Placebo is given subcutaneously (SC) every two weeks
Treatment: CM310
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis
- Publications
- Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial.JAMA, 2025
- Anti-IL-4Rα monoclonal antibody (CM310) in patients with chronic rhinosinusitis with nasal polyps (CROWNS-2): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.Asia Pacific allergy, 2024
- Record updated
- 8 November 2024